HLB Panagene to Present Artificial Nucleic Acid Research Achievements at Global Conference

HLB Panagene will showcase its artificial nucleic acid (PNA) research achievements at the 22nd Oligonucleotide Therapeutics Society (OTS 2026) to be held from October 11 to 14.

According to HLB Panagene on September 29, the study analyzes how the type and position of chemical modifications applied to PNA affect the splicing regulatory effects. Splicing is an “editing process” in which unnecessary parts are removed and only essential parts are retained in RNA before proteins are synthesized. By regulating this process, it is possible to alter the proteins produced.

HLB Panagene explained that this research demonstrates the potential to extend its accumulated PNA technology in diagnostics to the next-generation oligonucleotide therapeutics field.

In particular, this research is expected to serve as a core foundational technology for the development of AOC (antibody-oligonucleotide conjugates), which is currently under preparation. This is because the accumulated expertise in optimizing PNA sequences and chemical modifications can be applied to the design and efficacy improvement of PNA payloads conjugated to AOCs.

An official from HLB Panagene stated, “The OTS 2026 presentation will be an opportunity to demonstrate the competitiveness of our PNA design and chemical modification technologies developed over the years, as well as to verify the potential for expansion into therapeutic applications on a global stage.” The official added, “We plan to utilize the technology and data secured through this research to drive the development of PNA-based new drugs and AOC candidates, while also actively seeking to expand our global partnerships.”

This content was produced with the assistance of AI translation services.